Intensive BP control can modify risk associated with elevated troponin T and natriuretic peptide levels: JAMA Medha Baranwal17 Sept 2021 10:30 AM ISTUSA: A recent study has noted that the risk of heart failure and death in people with elevated hs-cTnT and NT-proBNP levels can be modified with...
Dapagliflozin reduces risk of sudden cardiac death, ventricular arrhythmia in HFrEF patients: Study Medha Baranwal6 Sept 2021 9:00 AM ISTUK: A recent study has found that dapagliflozin when added to conventional therapy in HFrEF patients reduces the risk of cardiac arrest, any serious...
Exercise-induced oxidative stress predicts poor prognosis in HF patients: Study Hina Zahid4 Sept 2021 9:00 AM ISTJapan: Heart failure (HF) patients who underwent a cardiopulmonary exercise test and showed an increase in oxidative stress had a poor prognosis, show...
Beta blockers may reduce mortality in cluster of young patients with AF and HF: Lancet Dr. Shravani Dali2 Sept 2021 10:45 AM ISTA statistically significant reduction in mortality is associated with beta blockers in a cluster of younger atrial fibrillation patients at lower...
Drinking sufficient water could reduce risk of heart failure: Study Hina Zahid1 Sept 2021 9:00 AM ISTSophia Antipolis, France - Staying well hydrated throughout life could reduce the risk of developing heart failure, according to research...
Empagliflozin significantly reduces hospitalization risk in patients of HFpEF, shows trial Dr. Kamal Kant Kohli30 Aug 2021 6:00 AM ISTFrance: SGLT-2 inhibitor, Empagliflozin significantly reduced heart failure-related hospitalizations, regardless of patient diabetes status, reveal...
Antiplatelet medicine may have potential as low-cost treatment for heart failure: Study Hina Zahid25 Aug 2021 9:00 AM ISTA new study has found that FDA-approved antiplatelet medication sarpogrelate significantly suppressed cardiomyocyte hypertrophy.USA: According to...
FDA approves empagliflozin for heart failure with reduced ejection fraction in adults Dr. Kamal Kant Kohli21 Aug 2021 7:15 AM ISTThe U.S. Food and Drug Administration has approved Jardiance (empagliflozin) to reduce the risk of cardiovascular mortality plus hospitalization for...
Dapagliflozin a cost-effective adjunct therapy for chronic HFrEF: Study Dr. Shravani Dali21 Aug 2021 6:15 AM ISTDapagliflozin is an economical adjunct therapy to usual care for the management of chronic heart failure and reduced ejection fraction (HFrEF),...
Dapagliflozin reduces risk for hyperkalemia in HFrEF patients treated with MRAs: Study Dr. Shravani Dali20 Aug 2021 9:00 AM ISTDapagliflozin Reduces Hyperkalemia Risk in Heart Failure and reduced ejection fraction (HFrEF) in patients treated with mineralocorticoid receptor...
Early coronary angiography improves cardiovascular outcomes in patients with acute heart failure: Study Medha Baranwal16 Aug 2021 9:15 AM ISTCanada: Early coronary angiography during acute heart failure (HF) hospitalization is associated with lower HF readmissions, cardiovascular death,...
Serum aldosterone independent predictor of HFpEF prognosis: Study Hina Zahid9 Aug 2021 8:15 PM ISTChina: The level of serum aldosterone is independently associated with all-cause mortality and primary endpoint in heart failure with a preserved...
